Clinical Trials
25
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 294
- Registration Number
- NCT06973564
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 334
- Registration Number
- NCT06959615
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳ShanXi Cancer Hospital, Taiyuan, Shanxi, China
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
- Conditions
- Advanced Non-squamous Non-small-cell Lung CancerMetastatic Non-squamous Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Allist Pharmaceuticals, Inc.
- Target Recruit Count
- 392
- Registration Number
- NCT06416410
- Locations
- 🇨🇳
Anhui Province cancer hospital, Hefei, Anhui, China
🇨🇳Pecking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital Chinese Academy Of Medical Sciences, Beijing, Beijing, China
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 144
- Registration Number
- NCT06386146
- Locations
- 🇨🇳
Research Site, Shanghai, Shanghai, China
🇺🇸Research site, Houston, Texas, United States
A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Allist Pharmaceuticals, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT06162169
- Locations
- 🇨🇳
Beijing GoBroad Hospital, Beijing, Beijing, China
- Prev
- 1
- 2
- 3
- 4
- 5
- Next